Hepatocellular carcinoma is a serious form of liver cancer that requires comprehensive medical attention, combining multiple treatment strategies tailored to each patient’s unique situation and the stage of their disease.

How Treatment Choices Depend on Your Specific Situation

When someone receives a diagnosis of hepatocellular carcinoma, the path forward depends on many factors working together. The treatment approach is shaped by how advanced the cancer is, how well the liver itself is functioning, and the overall health status of the patient. Because this cancer most often develops in people who already have chronic liver disease or cirrhosis—a condition where the liver is severely scarred—doctors must carefully balance treating the cancer while protecting what liver function remains.^[1]

Hepatocellular carcinoma often grows slowly at first, which can be deceiving. Many people do not experience symptoms until the cancer has advanced to a more serious stage. By that time, treatment becomes more challenging. This is why individuals with liver disease, especially cirrhosis, are encouraged to have regular screening tests every six months. Early detection dramatically improves the chances of successful treatment, including potentially curative options like surgery or liver transplantation.^[2]

The medical community uses staging systems to categorize hepatocellular carcinoma and guide treatment decisions. The most widely adopted is the Barcelona Clinic Liver Cancer (BCLC) staging system, which takes into account tumor characteristics, liver function measured by the Child-Pugh classification, and the patient’s physical performance status. This comprehensive approach ensures that treatment recommendations fit the whole picture of a person’s health, not just the cancer alone.^[14]

Approximately 80% to 90% of people diagnosed with hepatocellular carcinoma also have cirrhosis, which profoundly affects treatment options. The presence of both conditions means that any therapy must address the cancer without causing the remaining healthy liver tissue to fail. This delicate balance requires expertise and careful monitoring throughout treatment.^[3]

Standard Approaches to Managing Hepatocellular Carcinoma

For patients diagnosed with early-stage hepatocellular carcinoma, surgery offers the best chance of cure. Partial hepatectomy—a surgical procedure where doctors remove the portion of the liver containing the tumor along with some surrounding healthy tissue—can be performed when the cancer is localized and the remaining liver is healthy enough to compensate. The liver has a remarkable ability to regenerate, and the remaining tissue can take over the functions of the removed portion.^[15]

Liver transplantation represents another potentially curative option, particularly for patients whose cancer has not spread beyond the liver and who meet specific criteria. During transplantation, the entire diseased liver is removed and replaced with a healthy donor liver. This approach not only eliminates the cancer but also addresses the underlying cirrhosis. However, the availability of donor organs is limited, and patients often require other treatments while waiting for a suitable liver to become available. Only about 5% of hepatocellular carcinoma patients are suitable candidates for transplantation, but those who receive this treatment may achieve five-year survival rates greater than 75%.^[12]

When surgery is not feasible due to tumor location, size, or the patient’s overall health, ablation therapies provide alternatives. These techniques destroy cancer tissue without removing it. Radiofrequency ablation uses high-energy radio waves delivered through special needles inserted directly into the tumor. The heat generated kills cancer cells. Microwave therapy works similarly, using microwaves to create high temperatures that damage and destroy cancer cells. Another option is percutaneous ethanol injection, where pure alcohol is injected directly into the tumor to kill cancer cells. These procedures are typically performed by interventional radiologists and may be done under local anesthesia, though general anesthesia is sometimes used for patients with multiple tumors.^[10]

Embolization therapy is designed for patients who cannot undergo surgery or ablation and whose cancer has not spread outside the liver. This approach takes advantage of the fact that tumors receive most of their blood supply from the hepatic artery, while healthy liver tissue receives blood primarily from another vessel called the hepatic portal vein. In transarterial embolization (TAE), doctors insert a catheter through a small incision in the inner thigh and guide it to the hepatic artery. They then inject substances that block blood flow to the tumor, essentially starving it of oxygen and nutrients. Transarterial chemoembolization (TACE) combines this blocking effect with chemotherapy drugs, either attached to tiny beads or injected directly, maximizing the cancer-fighting effect while minimizing exposure to healthy tissue.^[15]

For advanced hepatocellular carcinoma that has spread beyond the liver or cannot be treated with local therapies, systemic treatments become necessary. Sorafenib was the first targeted therapy approved for advanced hepatocellular carcinoma. It is a tyrosine kinase inhibitor that works by blocking proteins involved in tumor growth and the formation of new blood vessels that feed the tumor. Sorafenib is taken orally as a pill, typically twice daily. Common side effects include skin problems on the hands and feet, diarrhea, fatigue, and high blood pressure. Regular monitoring is essential to manage these side effects and adjust the dose if needed.^[6]

Several other targeted therapies have been approved based on clinical trial results. Lenvatinib is another tyrosine kinase inhibitor that can be used as a first-line treatment for advanced disease. Regorafenib and cabozantinib are options for patients whose disease has progressed after initial treatment with sorafenib. Ramucirumab, which targets a specific receptor involved in blood vessel formation, is approved for patients with elevated levels of a protein called alpha-fetoprotein. Each of these medications has its own side effect profile, and doctors work closely with patients to manage any problems that arise during treatment.^[6]

Immunotherapy represents a newer approach that harnesses the body’s own immune system to fight cancer. Atezolizumab combined with bevacizumab has become a standard first-line treatment for advanced hepatocellular carcinoma. Atezolizumab is a checkpoint inhibitor that blocks a protein called PD-L1, essentially taking the brakes off the immune system so it can attack cancer cells. Bevacizumab blocks a protein called VEGF, which tumors use to grow new blood vessels. Together, these drugs work through complementary mechanisms. Another immunotherapy combination is durvalumab (also a PD-L1 inhibitor) with tremelimumab (which blocks another checkpoint protein called CTLA-4). These combinations have shown significant benefits in clinical trials and are changing the landscape of hepatocellular carcinoma treatment.^[6]

Treatment duration varies depending on the approach. Surgery and ablation procedures are typically one-time interventions, though follow-up monitoring continues indefinitely to watch for cancer recurrence. Embolization procedures may be repeated if needed. Systemic therapies with targeted drugs or immunotherapy are usually continued as long as the treatment is controlling the disease and side effects remain manageable. Regular imaging studies and blood tests help doctors assess how well the treatment is working and make adjustments as necessary.^[12]

Promising Therapies Being Tested in Clinical Trials

Research into new treatments for hepatocellular carcinoma is rapidly advancing, with numerous clinical trials exploring innovative approaches. Clinical trials proceed through several phases, each designed to answer specific questions. Phase I trials primarily assess safety and determine appropriate dosing in a small number of patients. Phase II trials evaluate whether the treatment shows promise in fighting cancer and continue to monitor safety in a larger group. Phase III trials compare the new treatment against current standard therapies to determine if it offers superior outcomes.^[6]

One major area of investigation involves combining different types of immunotherapy. Researchers are testing whether using two checkpoint inhibitors together might produce better results than single-agent therapy. These combinations aim to activate the immune system through multiple pathways simultaneously, potentially overcoming cancer’s ability to evade immune detection. Early results from some of these studies have been encouraging, showing improved response rates and survival in certain patient populations.^[13]

Another promising strategy combines immunotherapy with targeted therapies that affect blood vessel formation or cancer cell growth pathways. The rationale is that these approaches work through different mechanisms and might complement each other. For example, anti-VEGF drugs that block blood vessel formation might make tumors more accessible to immune cells, while checkpoint inhibitors activate those immune cells to attack the cancer. Several such combination studies are ongoing at major cancer centers worldwide, including locations in the United States, Europe, and Asia.^[13]

Researchers are also investigating novel targeted therapies that attack specific molecular vulnerabilities in hepatocellular carcinoma cells. Approximately 25% of all hepatocellular carcinomas have potentially targetable mutations—genetic changes that could be exploited with specifically designed drugs. Scientists are working to translate these molecular discoveries into clinical treatments. Some trials are testing drugs that target mutations in specific genes involved in cell growth control, DNA repair, or other critical cellular functions. These precision medicine approaches aim to match each patient’s tumor characteristics with the most appropriate therapy.^[6]

Clinical trials are exploring electroporation therapy, which uses electrical pulses delivered through an electrode placed in the tumor to kill cancer cells. This technique is being studied as an alternative ablation method that might be effective for tumors in locations where radiofrequency ablation is difficult or risky. Early-phase trials are assessing the safety and preliminary efficacy of this approach in patients with early to intermediate-stage disease.^[15]

Some research focuses on improving existing therapies. For example, investigators are studying whether drug-eluting beads used in embolization procedures can be optimized to deliver chemotherapy more effectively to tumors while further reducing side effects. Other studies are examining the optimal timing and sequencing of different treatments—for instance, whether using ablation or embolization before systemic therapy might improve overall outcomes compared to systemic therapy alone.^[12]

Eligibility for clinical trials depends on multiple factors, including the stage of cancer, previous treatments received, liver function status, and overall health. Many trials are conducted at specialized cancer centers and academic medical institutions. Patients interested in participating in clinical trials should discuss this option with their healthcare team, who can help identify appropriate studies and explain the potential benefits and risks. Clinical trial participation offers access to cutting-edge treatments that are not yet widely available and contributes to advancing medical knowledge that may help future patients.^[6]

Most Common Treatment Methods

• Surgical Treatments
  • Partial hepatectomy removes the portion of liver containing the tumor along with surrounding healthy tissue, allowing the remaining liver to regenerate and take over full function
  • Liver transplantation replaces the entire diseased liver with a healthy donor organ, addressing both the cancer and underlying cirrhosis simultaneously
  • Candidates for surgery must have adequate liver function and overall health to tolerate the procedure and recovery period
• Ablation Therapies
  • Radiofrequency ablation uses high-energy radio waves delivered through needles to heat and destroy cancer tissue directly
  • Microwave therapy employs microwaves to generate high temperatures that damage and kill cancer cells
  • Percutaneous ethanol injection delivers pure alcohol directly into tumors to destroy cancer cells
  • Cryoablation freezes cancer cells using specialized instruments, guided by ultrasound imaging
• Embolization Procedures
  • Transarterial embolization (TAE) blocks blood flow to tumors through the hepatic artery, starving cancer cells of oxygen and nutrients
  • Transarterial chemoembolization (TACE) combines arterial blockage with chemotherapy delivery, either attached to beads or injected directly
  • These procedures take advantage of the fact that tumors primarily receive blood from the hepatic artery while healthy liver tissue receives blood from the portal vein
• Targeted Therapy
  • Sorafenib blocks tyrosine kinases and proteins involved in tumor growth and blood vessel formation, taken as oral medication
  • Lenvatinib provides another tyrosine kinase inhibitor option for first-line treatment of advanced disease
  • Regorafenib and cabozantinib serve as second-line options when disease progresses after initial treatment
  • Ramucirumab targets VEGF receptors and is approved for patients with elevated alpha-fetoprotein levels
• Immunotherapy
  • Atezolizumab plus bevacizumab combines a PD-L1 checkpoint inhibitor with a VEGF inhibitor, working through complementary mechanisms to activate immune response and limit tumor blood supply
  • Durvalumab plus tremelimumab combines two different checkpoint inhibitors (anti-PD-L1 and anti-CTLA-4) to activate the immune system through multiple pathways
  • These treatments work by removing the brakes on the immune system, allowing it to recognize and attack cancer cells more effectively